Institut Paoli-Calmettes
Institut Paoli-Calmettes is a French non-profit Comprehensive Cancer Center in Marseille providing integrated oncology care, research, and prevention across all cancer types. It serves as a national and European reference center for rare tumors within the Unicancer federation of 18 French cancer centers.
- Company typePrivate
- Founded1923
- HeadquartersMarseille-en-beauvaisis, France
- Headcount1,001–5,000
- GTM typeB2C
- OfferingServices
What Institut Paoli-Calmettes does
Institut Paoli-Calmettes (IPC) is a French non-profit Comprehensive Cancer Center headquartered in Marseille, founded in 1923 and operating under French public health law as a Centre de Lutte Contre le Cancer within the Unicancer federation of 18 French cancer centers. The institution provides integrated oncology services across the full care continuum — prevention, diagnosis, medical oncology, surgical oncology (including robotic and minimally invasive surgery), radiotherapy, nuclear medicine, hematology and cell therapy, supportive care, and rehabilitation — serving adult, elderly, adolescent and young adult patients with all cancer types across southeastern France and beyond. It holds OECI Comprehensive Cancer Center accreditation, HAS certification with the 'Haute Qualité des soins' mention, ENETS Center of Excellence status, and serves as a national reference center for neuroendocrine tumors (RENATEN, TENpath) and as one of 25 reference centers in the NETSARC+ sarcoma network.
The center's technology stack centers on advanced diagnostics and therapeutics rather than a software platform: a Da Vinci Single Port (SP) robotic surgical system (first in the PACA region), the proprietary CINSARC molecular signature for soft tissue sarcoma prognosis, vectorized internal radiotherapy with LUTATHERA for neuroendocrine tumors, an INCa-labeled CLIP2 early-phase clinical trial unit, and a Centre de Ressources Biologiques holding 200,000+ biological samples (tissues, blood cells, serum, DNA, RNA) supporting translational research. Patient access is delivered through multi-modal channels including direct phone scheduling (Bureau des Rendez-Vous), physician-to-physician consultations, Doctolib online booking for selected services, IPC Connect telemedicine, and regional outreach consultations at four partner hospitals.
Revenue is generated primarily through French public health insurance (Sécurité Sociale) reimbursement under national fee schedules for the standard care activity, supplemented by institutional and pharmaceutical-funded clinical trial revenue (conducted as promoter or investigating center across INCa, European network, and industry partnerships), and private donations (eligible for 66% income tax, 75% IFI, and 60% corporate tax deductions). As a non-profit CLCC, IPC is not equity-financed and does not pursue capital-market growth; expansion is funded through operating surplus, public capital allocations, and philanthropic giving. Governance sits with Unicancer as the parent federation, with Pr Norbert VEY serving as Directeur général and Head of Hematology.
Institut Paoli-Calmettes firmographics
Firmographics- Name
- Institut Paoli-Calmettes
- Legal name
- Institut Paoli-Calmettes
- Website
- https://institutpaolicalmettes.fr
- Company type
- Private
- Founded year
- 1923
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Institut Paoli-Calmettes is a French non-profit Comprehensive Cancer Center in Marseille providing integrated oncology care, research, and prevention across all cancer types. It serves as a national and European reference center for rare tumors within the Unicancer federation of 18 French cancer centers.
- Ownership category
- akta.pro rank
Institut Paoli-Calmettes industry classification
Industry- Product category
- Oncology Hospital Services
- NAICS
- Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)
- akta.pro secondary industries
- Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL), Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL)
Keywords
Where Institut Paoli-Calmettes is headquartered
LocationHeadquarters
- HQ city
- Marseille-en-beauvaisis
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Institut Paoli-Calmettes business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Others, Marketing or Sales
Revenue model
- Public Healthcare Services: IPC operates as a public cancer center (Centre de Lutte Contre le Cancer) under the French public health code, providing cancer care services reimbursed through the French social security system (Sécurité Sociale). Patient payments are covered through public health insurance and complementary insurance.
- Clinical Research: Revenue from clinical trials conducted as promoter or investigating center, funded by institutional grants, pharmaceutical partnerships, and government cancer research funding (INCa, European networks)
- Private Donations: Private donations from individuals supporting cancer research and innovation programs. Donors can specify program preferences or leave allocation to IPC discretion. Tax deductions available (66% income tax, 75% IFI, 60% corporate tax)
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Patient hotel lodging near IPC for distant patients |
| Subscription | Monthly | Television services in patient rooms |
| Other | — | Doctolib online booking for specified services |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels8 records
Institut Paoli-Calmettes product offering
Product offeringCore offering
Institut Paoli-Calmettes (IPC) is a Comprehensive Cancer Center providing integrated oncology care for adult cancer patients across the full spectrum: medical oncology (chemotherapy, immunotherapy, targeted therapy), surgical oncology (open, minimally invasive, robotic), radiation therapy and nuclear medicine (including LUTATHERA vectorized internal radiotherapy), hematology and stem cell transplantation, oncogenetics, and supportive care. As a Centre de Lutte Contre le Cancer (CLCC) within the Unicancer federation, IPC also conducts translational and clinical research (including early-phase trials under CLIP² label), maintains a 200,000+ sample Biological Resources Center, and runs prevention, training, and patient-education programs reimbursed through the French Sécurité Sociale public health insurance system.
Differentiator
Problem solved
Functional benefit
Products and services
- IPC Connect Telemedicine Platform Web and mobile application providing remote teleconsultations, secure access to medical records, and digital healthcare coordination for cancer patients and their physicians.
- Doctolib Online Appointment Booking Online scheduling service for new patients to book mammographies, breast ultrasounds, onco-urology consultations, and breast surgery appointments directly through the Doctolib platform.
- CLIP²-Certified Early-Phase Clinical Trials Program (ETOH) INCa-labeled Center for Early Phase Clinical Investigations in onco-hematology, conducting Phase 1 and Phase 2 oncology and hematology clinical trials for patients.
- Oncogenetic Counseling (DASC Department) Clinical oncogenetics service providing hereditary cancer risk assessment, genetic testing, family screening, personalized prevention plans, and targeted surveillance for patients with cancer predisposition syndromes (BRCA, Lynch, Li-Fraumeni, VHL, FAP, MEN).
- Adolescents and Young Adults (AJA) Oncology Program Specialized oncology care for patients aged 18-30 with cancer, including dedicated coordinator, multidisciplinary psychological and social support, adapted physical activity, fertility preservation, and educational and professional reintegration support.
- Oncogeriatric Care Service Multidisciplinary oncology care combining oncologists and geriatricians to address aging-related vulnerabilities, functional reserves, comorbidities, and treatment toxicity in elderly cancer patients.
- LUTATHERA Vectorized Internal Radiotherapy Specialized Radiothérapie Interne Vectorisée using LUTATHERA (lutetium-177) for neuroendocrine tumor treatment, available at IPC since 2016.
- Da Vinci Single Port (SP) Robotic Surgery Single-incision robotic surgery using the Da Vinci SP system for minimally invasive oncological procedures; IPC is the fourth establishment in France and first in PACA region to acquire this technology.
- DIEP Free Flap Breast Reconstruction Autologous breast reconstruction performed by microsurgery after mastectomy using the patient's own tissues via DIEP (Deep Inferior Epigastric Perforator) free flap technique.
- vNOTES Sentinel Lymph Node Procedure Minimally invasive gynecological surgery using the vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) approach for sentinel pelvic lymph node procedures.
- Patient Hotel Lodging Furnished apartment lodging near IPC for patients traveling more than 100 km for treatment, billed at 20 euros per night.
- In-Room Patient Television Subscription Paid bouquet of TV channels available in patient rooms at IPC, with a free internal IPC channel option.
- Photon Scanner Imaging Service New photon scanner installation project supporting cancer research and diagnosis, available as a research program supported by private donations.
Quantifiable outcome
- IPC ranked among best hospitals in France for multiple specialties in Le Point annual rankings
- +4 more outcomes
Companies that use Institut Paoli-Calmettes
Customer profileNamed customers5 records
Segments6 records
Ideal customer profiles4 records
Institut Paoli-Calmettes technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Institut Paoli-Calmettes partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered flagship, core and minor.
- EURACAN (European Reference Network for Rare Adult Solid Cancers)flagshipEuropean network of 66 establishments for rare adult solid cancers. IPC is reference center for neuroendocrine tumors (one of 4 centers in France). Mission: improve diagnosis, access to innovative care, and promote clinical trial cooperation for rare cancers.
- ENETS (European Neuroendocrine Tumor Society)flagshipEuropean reference network with 57 centers across Europe. IPC holds Center of Excellence designation since 2017, re-evaluated every 5 years. The only CLCC in France with this designation. Enables access to expertise, innovation, and optimal multidisciplinary care for neuroendocrine tumors.
- RENATEN (Réseau National de prise en charge des Tumeurs Neuroendocrines)flagshipNational network created under INCa leadership in 2010. Coordinates 23 regional competence centers across France, led by 4 national reference centers (IPC, Paris, Lyon). Objective: equitable specialized care and innovation access for all neuroendocrine tumor patients.
- IRCADcorePartnership with IRCAD (Institut de Recherche contre les Cancers de l'Appareil Digestif), a world reference for training in endoscopy and minimally invasive surgery. From April 2020, IPC oncological endoscopy training cases are conducted at IRCAD facilities.
- TENpath (réseau national d'anatomopathologie dédié aux tumeurs neuroendocrines)coreNational pathology network dedicated to neuroendocrine tumors. IPC provides expert anatomopathological expertise and performs double readings of surgical specimens and biopsies for the region.
- Oncodistinct European NetworkcoreEuropean oncology research network enabling IPC participation in international clinical trials and collaborative research across multiple cancer types.
- Segal Cancer Centre (Montréal, Canada)coreInternational research partnership for cancer treatment and research collaboration between IPC Marseille and Segal Cancer Centre in Montreal, Canada.
- Moffitt Cancer Center (Florida, USA)coreInternational research collaboration with Moffitt Cancer Center in Tampa, Florida, USA, focusing on cancer research and treatment innovations.
- Karolinska Institute (Sweden)coreResearch partnership with Karolinska Institute in Sweden for international oncology research collaboration.
- TGEN-TD2 (Arizona, USA)coreInternational research partnership with TGen (The Translational Genomics Research Institute) and TD2 in Arizona, USA for cancer research collaboration.
- Rui Jin Hospital (Shanghai, China)coreResearch collaboration with Rui Jin Hospital in Shanghai, China for international oncology studies.
- Applied Research on Cancer (Verona, Italy)coreInternational research partnership with ARC (Applied Research on Cancer) in Verona, Italy for cancer treatment and research collaboration.
- CRLC Antoine Lacassagne (Nice, France)coreRegional partnership for neuroendocrine tumor care. Dr Eric François and Dr Claire Jaraudias from CRLC Antoine Lacassagne participate in weekly RCP RENATEN ENETS multidisciplinary meetings with IPC team.
- Institut St Catherine (Avignon, France)coreRegional partnership for neuroendocrine tumor care. Dr Laurent Mineur and Dr Clémence Toullec from Institut St Catherine participate in weekly RCP RENATEN ENETS multidisciplinary meetings with IPC team.
- CHICAS Hôpital de GapminorRegional partnership for oncogenetic consultations. Dr Jessica Moretta provides weekly advanced consultations at CHICAS Hôpital de Gap as part of IPC's regional outreach.
- CH de MartiguesminorRegional partnership for oncogenetic consultations. Dr Jessica Moretta provides weekly advanced consultations at CH de Martigues as part of IPC's regional outreach.
- CHIPL Hôpital d'Aix en ProvenceminorRegional partnership for oncogenetic consultations. Dr Jessica Moretta provides weekly advanced consultations at CHIAP Hôpital d'Aix en Provence as part of IPC's regional outreach.
- Hôpital privé la CasamanceminorRegional partnership for oncogenetic consultations. Dr Jessica Moretta provides weekly advanced consultations at Hôpital privé la Casamance as part of IPC's regional outreach.
- NETSARC+ NetworkflagshipINCa-labeled care and research network for sarcomas and connective tissue tumors. IPC is one of 25 reference centers in France. Network ensures quality diagnosis (expert pathology review) and treatment for sarcoma patients.
Scale indicators7 records
Recent moves7 records
Expansion highlights7 records
Institut Paoli-Calmettes competitors and assessment
Company assessmentDirect peers
- Gustave Roussy: Gustave Roussy is the largest French Comprehensive Cancer Center and a fellow Unicancer CLCC. It is directly comparable to IPC in scope (multidisciplinary oncology, research, teaching) but operates at a national/international scale.
- Institut Curie: Institut Curie is a Paris-based comprehensive cancer center combining hospital care, research, and teaching. It is a direct peer to IPC in full-spectrum oncology, with additional historical strength in radiotherapy.
- Centre Léon Bérard: Centre Léon Bérard (Lyon) is a Unicancer CLCC providing comprehensive cancer care, research, and prevention. It is a direct peer to IPC with a similar service model and referral-network role in its region.
- Institut Bergonié: Institut Bergonié (Bordeaux) is a Unicancer CLCC with multidisciplinary oncology and research focus, including a strong sarcoma program. Direct peer to IPC, particularly in rare-tumor reference center activities.
- Institut de Cancérologie de l'Ouest (ICO): ICO is a French comprehensive cancer center with two sites (Angers, Saint-Herblain) providing oncology care, research, and prevention. Direct peer to IPC under the Unicancer network.
- IUCT-Oncopole: IUCT-Oncopole (Toulouse) is a French comprehensive cancer center integrating care, research, and innovation. Direct peer to IPC, with similar academic hospital integration and clinical research depth.
- Centre Georges-François Leclerc: Centre Georges-François Leclerc (Dijon) is a French CLCC offering comprehensive cancer treatment and translational research. Direct peer to IPC within the Unicancer federation.
- Centre François Baclesse: Centre François Baclesse (Caen) is a Unicancer CLCC delivering multidisciplinary oncology care and research. Direct peer to IPC in the French CLCC federation.
Regional players
- Karolinska Comprehensive Cancer Center: Karolinska is a leading European academic cancer center and an IPC research partner. It is a relevant European peer with similar comprehensive cancer center and translational research profile, but operates in Sweden.
- Moffitt Cancer Center: Moffitt is a US NCI-designated Comprehensive Cancer Center and an IPC research partner. Comparable in research and translational depth, but operates in the US healthcare system with different reimbursement dynamics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Institut Paoli-Calmettes social profiles
Digital presenceInstitut Paoli-Calmettes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Institut Paoli-Calmettes leadership team
Management profileNumber of profiles
Profiles8 records
Institut Paoli-Calmettes funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Institut Paoli-Calmettes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Institut Paoli-Calmettes
What does Institut Paoli-Calmettes do?
Institut Paoli-Calmettes (IPC) is a Comprehensive Cancer Center providing integrated oncology care for adult cancer patients across the full spectrum: medical oncology (chemotherapy, immunotherapy, targeted therapy), surgical oncology (open, minimally invasive, robotic), radiation therapy and nuclear medicine (including LUTATHERA vectorized internal radiotherapy), hematology and stem cell transplantation, oncogenetics, and supportive care. As a Centre de Lutte Contre le Cancer (CLCC) within the Unicancer federation, IPC also conducts translational and clinical research (including early-phase trials under CLIP² label), maintains a 200,000+ sample Biological Resources Center, and runs prevention, training, and patient-education programs reimbursed through the French Sécurité Sociale public health insurance system.
Is Institut Paoli-Calmettes a public or private company?
Institut Paoli-Calmettes is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Institut Paoli-Calmettes founded?
Institut Paoli-Calmettes was founded in 1923. It employs 1,001 to 5,000 people.
Where is Institut Paoli-Calmettes based?
Institut Paoli-Calmettes is headquartered in Marseille-en-beauvaisis, France, in the Europe region.
How does Institut Paoli-Calmettes make money?
Three revenue lines are on record. Public Healthcare Services are the primary driver. The others are clinical Research and private Donations.
Who are Institut Paoli-Calmettes's main competitors?
Direct peers on record are Gustave Roussy, Institut Curie, Centre Léon Bérard, Institut Bergonié, Institut de Cancérologie de l'Ouest (ICO), IUCT-Oncopole, Centre Georges-François Leclerc and Centre François Baclesse. Regional players are Karolinska Comprehensive Cancer Center and Moffitt Cancer Center.
Does Institut Paoli-Calmettes have an API?
No public API is recorded for Institut Paoli-Calmettes.
What industry is Institut Paoli-Calmettes in?
Institut Paoli-Calmettes's product category is Oncology Hospital Services. Its primary akta.pro industry code is HLAFAAAM, Hospital-Integrated Cancer Centers (Acute Oncology Programs), with a secondary code of HLAFABAI, Ambulatory Oncology Centers (Outpatient Chemo/Radiation). Its NAICS code is 62231 and its SIC code is 8000.